Modified growth hormone fragment
AOD-9604
Human clinical trialsA fragment of growth hormone once developed as an obesity drug.
Evidence
Human clinical trials
Regulatory status
Not FDA-approved.
Class
Modified growth hormone fragment
What it is
AOD-9604 is a modified piece of the end of the human growth hormone molecule (amino acids 176–191), studied for fat metabolism without growth hormone’s other effects.
What the research shows
- It reached human clinical trials for obesity, but development stopped after trials did not show meaningful weight loss compared with placebo.
Read the published research on PubMed →
Researched for
AOD-9604 is not FDA-approved for the uses people commonly discuss. Its safety and effectiveness in people have not been established. Talk to a licensed provider before making any decision.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
GLP-1 receptor agonist
Semaglutide
A GLP-1 receptor agonist and one of the most studied peptide medicines in the world.
FDA-approved drugDual GIP / GLP-1 receptor agonistTirzepatide
The first approved medicine that activates both the GIP and GLP-1 receptors.
FDA-approved drugTriple GIP / GLP-1 / glucagon receptor agonistRetatrutide
An investigational "triple agonist" currently in late-stage clinical trials.
Human clinical trials